- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06334952
Efficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic (GALVANI GS-3)
March 21, 2024 updated by: Assistance Publique Hopitaux De Marseille
Model-based Multichannel Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epilepsy: A Cross-over Study of Efficacy
The goal of this clinical trial is to to obtain a significant decrease in seizure frequency in patients with refractory focal epilepsy after applying treatment of cathodal tDCS, compared to sham stimulation drug-resistant epileptic patient. The main questions it aims to answer are:
- Changes in quality of life
- Percent of newly reported side effects after the stimulation period
- Scores in epilepsy severity. Participants will be randomized in a cross-over, and will receive 10 days of tDCS or Sham. Each day will allow 2 periods of 20 minutes stimulation separated by 20 minutes off (with 40 minutes of cathodal stimulation total).
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fabrice Bartolomei, MD, PhD
- Phone Number: 33 0491384990
- Email: fabrice.bartolomei@ap-hpm.fr
Study Contact Backup
- Name: Sophie Tardoski
- Phone Number: 33 0491381594
- Email: sophie.tardoski@ap-hm.fr
Study Locations
-
-
-
Bordeaux, France, 33000
- Service de Neurophysiologie Clinique de l'Enfant et de L'Adulte, Pôle de Neurosciences Cliniques
-
Contact:
- Jerome Aupy
- Email: Jerome.aupy@chu-bordeaux.fr
-
Bron, France, 69677
- Département Neurologie Fonctionnelle et Epilepsie, Hôpital neurologique - Hospices Civils de Lyon
-
Contact:
- Sylvain Rheims
- Email: Sylvain.rheims@chu-lyon.fr
-
Lille, France, 59037
- Service de Neurophysiologie clinique - Hôpital Roger Salengro, CHU Lille
-
Contact:
- Philippe Derambure
- Email: Philippe.Derambure@chru-lille.fr
-
Marseille, France, 13005
- Service Epileptologie et Rythmologie Cérébrale, Hôpital La Timone
-
Contact:
- Fabrice Bartolomei
- Email: Fabrice.bartolomei@ap-hm.fr
-
Paris, France, 75014
- Service de Neurophysiologie clinique - GHU Psychiatrie et Neurosciences Sainte-Anne
-
Contact:
- Martine Gavaret
- Email: m.gavaret@ghu-paris.fr
-
Rennes, France, 35033
- Service de Neurologie - CHU de Rennes - Hôpital Pontchaillou
-
Contact:
- Anca Nica
- Email: Anca.nica@chu-rennes.fr
-
Toulouse, France, 31059
- Explorations neurophysiologiques - Pôle neurosciences, CHU de Toulouse, Hôpital Pierre Paul Riquet
-
Contact:
- Luc Valton
- Email: valton.l@chu-toulouse.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient, parents or legal representative who have given written informed consent;
- Age: ≥ 9 years;
- Patients with drug-resistant focal epilepsy with no surgical indication or with a previous surgical failure, refusing surgery or with a planned surgery compatible with the total duration of this study;
- SEEG previously performed before inclusion with an adequate definition of the epileptogenic zone (within 5 years before inclusion);
- Patient having a pre-SEEG 3D-T1 MRI and CT-scan with electrodes during SEEG available;
- A research MRI scan that is suitable for navigated brain stimulation (NBS) and generation of electrical fields including dMRI for tractography;
- Number of seizures ≥3/month during the baseline (before the first session of tDCS treatment);
- Patient having stable medications for epilepsy 4 weeks before the baseline (except rescue treatment);
- Patient's IQ, which in the investigator's opinion will enable questionnaires and neuropsychological assessments to be carried out;
- Patient able to understand, speak and write in French;
- Patient able to follow study's procedure;
- Patient beneficiary or affiliated to a health insurance plan.
Exclusion Criteria:
- Patients with seizures of generalized onset in the last 12 months;
- Patient with multifocal epileptogenic zones, bilateral epileptogenic zone, or poorly defined epileptogenic zone. The epileptogenic network should not be restricted to the orbito frontal cortex or cingulate cortex;
- Patients with a history of psychogenic nonepileptic seizures;
- Patient presenting a contraindication to MRI 3T (patient having a pacemaker, metallic foreign bodies, non-removably implanted electronic medical devices, claustrophobia, inability to remain in supine position, vagal nerve stimulator) ;
- Substance use disorder, as defined in DSM-V, within the past year;
- Patient presenting a serious intercurrent pathology and/or a progressive brain tumor
- Patient having damaged skin or scalp that may interfere with tDCS stimulation (e.g., eczema, lesion);
- Patient having any cranial metal implants such as shrapnel or surgical clips (excluding <1 mm thick epicranial titanium skull plates and dental fillings) or medical devices (i.e. cardiac pacemaker, deep brain stimulator, medication infusion pump, cochlear implant)
- Patient having previous surgeries opening the skull leaving skull defects capable of allowing the insertion of a cylinder with a radius greater or equal to 5 mm;
- Any condition that makes the study subject, in the opinion of the investigator, unsuitable for the study including presence of any disease, abnormality, medical or physical condition that, in the opinion of the investigator, may adversely impact, compromise, interfere, limit, affect or reduce the safety of the subject, the integrity of the data ;
- Person protected by articles L1121-5, L1121-6 and L1121-8 of Public Health Code (pregnant or breastfeeding woman, deprived of liberty by judicial decision, situations of social fragility, adults unable or unable to express their consent).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: tDCS - Sham
Patient will be randomized to firstly receive tDCS (10 non consecutive days, 20 minutes twice a day with 20 minutes of break) and then Sham (10 non consecutive days, 20 minutes twice a day with 20 minutes of break).
|
Research MRI includes 3D-T1 weighted MRI (3D-T1), diffusion MRI (dMRI), resting-state functional MRI (rsfMRI).
Other Names:
|
Other: Sham - tDCS
Patient will be randomized to firstly receive Sham (10 non consecutive days, 20 minutes twice a day with 20 minutes of break) and then tDCS (10 non consecutive days, 20 minutes twice a day with 20 minutes of break).
|
Research MRI includes 3D-T1 weighted MRI (3D-T1), diffusion MRI (dMRI), resting-state functional MRI (rsfMRI).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To obtain a significant seizure frequency change at the end of tDCS sessions compared to the seizure frequency calculated in the pre-treatment period of reference.
Time Frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Seizure frequency counting after end of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study.
|
Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
To obtain a significant seizure frequency change at the end of tDCS sessions compared to the seizure frequency calculated in the pre-treatment period of reference.
Time Frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Seizure frequency counting after end of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study.
|
V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
To obtain a significant seizure frequency change at the end of tDCS sessions compared to the seizure frequency calculated in the pre-treatment period of reference.
Time Frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Seizure frequency counting after end of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study.
|
V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
To obtain a significant seizure frequency change at the end of tDCS sessions compared to the seizure frequency calculated in the pre-treatment period of reference.
Time Frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Seizure frequency counting after end of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study.
|
V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the number of responders (defined as patient with >50% of seizure reduction)
Time Frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Proportion of responders evaluated after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
|
Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Evaluation of the number of responders (defined as patient with >50% of seizure reduction)
Time Frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Proportion of responders evaluated after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
|
V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Evaluation of the number of responders (defined as patient with >50% of seizure reduction)
Time Frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Proportion of responders evaluated after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
|
V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Evaluation of the number of responders (defined as patient with >50% of seizure reduction)
Time Frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Proportion of responders evaluated after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
|
V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Evaluate the number of seizure-free patients
Time Frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Number of seizure-free patients after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
|
Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Evaluate the number of seizure-free patients
Time Frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Number of seizure-free patients after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
|
V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Evaluate the number of seizure-free patients
Time Frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Number of seizure-free patients after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
|
V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Evaluate the number of seizure-free patients
Time Frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Number of seizure-free patients after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
|
V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Quality of life after stimulation sessions with the baseline period
Time Frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Changes from baseline in the quality of life questionnaire (QOLIE 31 for adults and EFIQUACEE QOL for children) after the stimulation period
|
Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Quality of life after stimulation sessions with the baseline period
Time Frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Changes from baseline in the quality of life questionnaire (QOLIE 31 for adults and EFIQUACEE QOL for children) after the stimulation period
|
V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Quality of life after stimulation sessions with the baseline period
Time Frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Changes from baseline in the quality of life questionnaire (QOLIE 31 for adults and EFIQUACEE QOL for children) after the stimulation period
|
V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Quality of life after stimulation sessions with the baseline period
Time Frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Changes from baseline in the quality of life questionnaire (QOLIE 31 for adults and EFIQUACEE QOL for children) after the stimulation period
|
V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Evaluation of the change in seizure severity
Time Frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Changes in the scores of epilepsy severity (NHS3) (investigator evaluation)
|
Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Evaluation of the change in seizure severity
Time Frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Changes in the scores of epilepsy severity (NHS3) (investigator evaluation)
|
V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Evaluation of the change in seizure severity
Time Frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Changes in the scores of epilepsy severity (NHS3) (investigator evaluation)
|
V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Evaluation of the change in seizure severity
Time Frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Changes in the scores of epilepsy severity (NHS3) (investigator evaluation)
|
V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Changes in psychiatric comorbidities
Time Frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Changes from baseline in depression (NDDI-E) and anxiety (GAD-7) scores
|
Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Changes in psychiatric comorbidities
Time Frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Changes from baseline in depression (NDDI-E) and anxiety (GAD-7) scores
|
V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Changes in psychiatric comorbidities
Time Frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Changes from baseline in depression (NDDI-E) and anxiety (GAD-7) scores
|
V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Changes in psychiatric comorbidities
Time Frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Changes from baseline in depression (NDDI-E) and anxiety (GAD-7) scores
|
V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Safety assessment and possible side effects
Time Frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Percent of newly reported side-effect during and after the stimulation period
|
Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Safety assessment and possible side effects
Time Frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Percent of newly reported side-effect during and after the stimulation period
|
V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Safety assessment and possible side effects
Time Frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Percent of newly reported side-effect during and after the stimulation period
|
V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Safety assessment and possible side effects
Time Frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Percent of newly reported side-effect during and after the stimulation period
|
V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare brain functional connectivity before and after tDCS treatment
Time Frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Changes in functional connectivity measured by fMRI and EEG signal 4 weeks after the tDCS periods in comparison with baseline period
|
V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
|
Evaluation of the impact of tDCS on interictal epileptic spikes (IESs)
Time Frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Change in the number of IESs per time unit after each tDCS session in comparison with baseline period
|
Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Evaluation of the impact of tDCS on interictal epileptic spikes
Time Frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Change in localization and extent of brain areas involved in IESs before and after each tDCS session in comparison with baseline period
|
Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Evaluation of the impact of tDCS on interictal epileptic spikes
Time Frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Change in localization and extent of brain areas involved in IESs before and after each tDCS session in comparison with baseline period
|
V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Evaluation of the impact of tDCS on interictal epileptic spikes
Time Frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Changes in strength and density of functional links during IES before and after each tDCS session
|
Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
|
Evaluation of the impact of tDCS on interictal epileptic spikes
Time Frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Changes in strength and density of functional links during IES before and after each DCS session
|
V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
May 31, 2026
Study Completion (Estimated)
April 30, 2027
Study Registration Dates
First Submitted
March 16, 2024
First Submitted That Met QC Criteria
March 21, 2024
First Posted (Actual)
March 28, 2024
Study Record Updates
Last Update Posted (Actual)
March 28, 2024
Last Update Submitted That Met QC Criteria
March 21, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RCAPHM23_0074
- ID-RCB (Other Identifier: 2019-A02945-52)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on transcranial direct current stimulation
-
Federal University of ParaíbaCompleted
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
University of Campinas, BrazilUnknownEpilepsy IntractableBrazil
-
Dina Hatem ElhammadyUnknown
-
Shirley Ryan AbilityLabNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedStroke | Nonfluent AphasiaUnited States
-
University of Texas Rio Grande ValleyRecruitingSpinal Cord Diseases | Spinal Cord InjuriesUnited States
-
Federal University of ParaíbaUnknown
-
University of CalgaryAlberta Health servicesRecruitingCervicogenic HeadacheCanada
-
Universidade Federal do Rio Grande do NorteNot yet recruitingLow Back Pain | Transcranial Direct Current Stimulation
-
Nanyang Technological UniversityActive, not recruiting